Your browser doesn't support javascript.
loading
Neisseria adhesin A variation and revised nomenclature scheme.
Bambini, Stefania; De Chiara, Matteo; Muzzi, Alessandro; Mora, Marirosa; Lucidarme, Jay; Brehony, Carina; Borrow, Ray; Masignani, Vega; Comanducci, Maurizio; Maiden, Martin C J; Rappuoli, Rino; Pizza, Mariagrazia; Jolley, Keith A.
Afiliação
  • Bambini S; Novartis Vaccines and Diagnostics, Siena, Italy.
  • De Chiara M; Novartis Vaccines and Diagnostics, Siena, Italy.
  • Muzzi A; Novartis Vaccines and Diagnostics, Siena, Italy.
  • Mora M; Novartis Vaccines and Diagnostics, Siena, Italy.
  • Lucidarme J; Public Health England, Manchester, United Kingdom.
  • Brehony C; Department of Zoology, University of Oxford, Oxford, United Kingdom.
  • Borrow R; Public Health England, Manchester, United Kingdom.
  • Masignani V; Novartis Vaccines and Diagnostics, Siena, Italy.
  • Comanducci M; Novartis Vaccines and Diagnostics, Siena, Italy.
  • Maiden MC; Department of Zoology, University of Oxford, Oxford, United Kingdom.
  • Rappuoli R; Novartis Vaccines and Diagnostics, Siena, Italy rino.rappuoli@novartis.com.
  • Pizza M; Novartis Vaccines and Diagnostics, Siena, Italy.
  • Jolley KA; Department of Zoology, University of Oxford, Oxford, United Kingdom.
Clin Vaccine Immunol ; 21(7): 966-71, 2014 Jul.
Article em En | MEDLINE | ID: mdl-24807056
Neisseria adhesin A (NadA), involved in the adhesion and invasion of Neisseria meningitidis into host tissues, is one of the major components of Bexsero, a novel multicomponent vaccine licensed for protection against meningococcal serogroup B in Europe, Australia, and Canada. NadA has been identified in approximately 30% of clinical isolates and in a much lower proportion of carrier isolates. Three protein variants were originally identified in invasive meningococci and named NadA-1, NadA-2, and NadA-3, whereas most carrier isolates either lacked the gene or harbored a different variant, NadA-4. Further analysis of isolates belonging to the sequence type 213 (ST-213) clonal complex identified NadA-5, which was structurally similar to NadA-4, but more distantly related to NadA-1, -2, and -3. At the time of this writing, more than 89 distinct nadA allele sequences and 43 distinct peptides have been described. Here, we present a revised nomenclature system, taking into account the complete data set, which is compatible with previous classification schemes and is expandable. The main features of this new scheme include (i) the grouping of the previously named NadA-2 and NadA-3 variants into a single NadA-2/3 variant, (ii) the grouping of the previously assigned NadA-4 and NadA-5 variants into a single NadA-4/5 variant, (iii) the introduction of an additional variant (NadA-6), and (iv) the classification of the variants into two main groups, named groups I and II. To facilitate querying of the sequences and submission of new allele sequences, the nucleotide and amino acid sequences are available at http://pubmlst.org/neisseria/NadA/.
Assuntos

Texto completo: 1 Bases de dados: MEDLINE Assunto principal: Adesinas Bacterianas / Vacinas Meningocócicas / Neisseria meningitidis Sorogrupo B / Meningite Meningocócica Limite: Humans Idioma: En Revista: Clin Vaccine Immunol Assunto da revista: ALERGIA E IMUNOLOGIA / TECNICAS E PROCEDIMENTOS DE LABORATORIO Ano de publicação: 2014 Tipo de documento: Article País de afiliação: Itália

Texto completo: 1 Bases de dados: MEDLINE Assunto principal: Adesinas Bacterianas / Vacinas Meningocócicas / Neisseria meningitidis Sorogrupo B / Meningite Meningocócica Limite: Humans Idioma: En Revista: Clin Vaccine Immunol Assunto da revista: ALERGIA E IMUNOLOGIA / TECNICAS E PROCEDIMENTOS DE LABORATORIO Ano de publicação: 2014 Tipo de documento: Article País de afiliação: Itália